Focal ablative therapy has emerged as a treatment option in radio-recurrent prostate cancer to obtain local control of disease and spare patients severe salvage-treatment-related complications. Irreversible electroporation holds the potential to become the standard ablative modality in prostate cancer owing to reliable ablation results, the electricity-based effect and an acceptable adverse-effect profile.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ma, T. M. et al. Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN). Eur. Urol. 82, 487–498 (2022).
Valle, L. F. et al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol. 80, 280–292 (2021).
Matei, D. V. et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol. Int. 94, 373–382 (2015).
Kanthabalan, A. et al. Intraprostatic cancer recurrence following radical radiotherapy on transperineal template mapping biopsy: implications for focal ablative salvage therapy. J. Urol. 204, 950–955 (2020).
Davalos, R. V., Mir, L. M. & Rubinsky, B. Tissue ablation with irreversible electroporation. Ann. Biomed. Eng. 33, 223–231 (2005).
Blazevski, A. et al. Salvage irreversible electroporation for radio-recurrent prostate cancer – the prospective FIRE trial. BJU Int. https://doi.org/10.1111/bju.15947 (2022).
Geboers, B. et al. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer. BJU Int. https://doi.org/10.1111/bju.15948 (2023).
Marra, G. et al. The SAFE Pilot Trial — SAlvage Focal Irreversible Electroporation — for recurrent localized prostate cancer: rationale and study protocol. Front. Surg. https://doi.org/10.3389/fsurg.2022.900528 (2022).
Jansen, B. H. E. et al. Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy. Eur. Urol. Oncol. 4, 821–825 (2021).
Acknowledgements
The authors thank B. Geboers, A. Blazevski and J. Matthews for their research and clinical support for their irreversible electroporation research line.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.J.S. received an educational grant from Angiodynamics. P.D.S. is a paid consultant to Angiodynamics. A.K. declares no competing interests.
Rights and permissions
About this article
Cite this article
Scheltema, M.J., Katelaris, A. & Stricker, P.D. Salvage irreversible electroporation for radio-recurrent prostate cancer. Nat Rev Urol 20, 517–518 (2023). https://doi.org/10.1038/s41585-023-00750-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-023-00750-1
